Table 2.
Baseline and final mineral-related biochemical changes
| Characteristics | Cholecalciferol |
Doxercalciferol |
Between-Treatment Group Pa | ||||
|---|---|---|---|---|---|---|---|
| Baseline (n = 22) | Final (n = 20) | Pre-Post P | Baseline (n = 25) | Final (n = 20) | Pre-Post P | ||
| Vitamin D (25(OH)D), ng/ml | 14.0 ± 6.1 | 37.2 ± 10.1 | <0.001 | 15.1 ± 5.5 | 14.0 ± 6.1 | 0.59 | <0.001 |
| Intact PTH, pg/ml | 109 ± 43 | 97 ± 49 | 0.15 | 106 ± 44 | 80 ± 49 | 0.006 | 0.19 |
| Phosphorus, mg/dl | 3.7 ± 0.4 | 3.9 ± 0.5 | 0.09 | 3.4 ± 0.6 | 3.6 ± 0.9 | 0.34 | 0.62 |
| Calcium, mg/dl | 9.0 ± 0.8 | 9.0 ± 0.6 | 0.80 | 9.1 ± 0.5 | 9.5 ± 0.9 | 0.04 | 0.15 |
| Urine calcium/creatinine ratio, mg/mg | 0.023 ± 0.04 | 0.013 ± 0.02 | 0.17 | 0.025 ± 0.03 | 0.04 ± 0.07 | 0.76 | 0.36 |
a
By repeated-measures two-way ANOVA with visit (baseline and end point), drug, and their interaction as factors.